Recent studies indicate that high YB-1 expression in glioma is associated with increased cell proliferation, survival, migration, and resistance to temozolomide (29, 34–36), and suggest YB-1 as a potential biomarker for glioma progression (37). Here, YBX1 is linked to central nervous system cancer.